Bimpe Adebayo
The offer closed well above expectations, recording a 117 per cent subscription rate—an outcome that positions it among the more strongly supported equity capital market transactions on the Nigerian Exchange Group in recent years.
Reflecting on the outcome, the firm described the transaction as a testament to both investor confidence and execution strength. “Acting as Financial Adviser and Issuing House, CardinalStone led the transaction from structuring and regulatory engagement through investor marketing, execution, and final allotment,” the company noted.
It added that the result highlights “strong execution capabilities, deep understanding of the Nigerian capital markets, and continued ability to connect credible businesses with long-term domestic capital.”
Despite broader macroeconomic pressures and liquidity constraints in the financial system, investor demand remained robust throughout the offer period. The 117 per cent oversubscription was widely interpreted as a signal of confidence in Fidson Healthcare’s long-term growth strategy and the broader resilience of Nigeria’s healthcare and manufacturing sectors.
“Despite prevailing macroeconomic and liquidity challenges, the 117 per cent oversubscription highlights strong investor confidence in Fidson’s growth strategy and the long-term potential of Nigeria’s healthcare and manufacturing sectors,” the statement read.
The strong uptake also points to sustained appetite for well-structured equity offerings, particularly those linked to essential sectors such as healthcare, where demand remains relatively stable even in volatile economic conditions.
Beyond its immediate financial outcome, the transaction carries broader implications for Nigeria’s industrial and healthcare development agenda. The country continues to depend heavily on imported pharmaceuticals and active ingredients, a situation that places pressure on foreign exchange reserves while exposing the health system to global supply disruptions.
Industry stakeholders argue that expanding local production capacity is increasingly critical—not only for healthcare security but also for macroeconomic stability. As highlighted in the announcement, “Nigeria continues to rely heavily on imported pharmaceutical products and active ingredients, creating significant pressure on foreign exchange demand while exposing the healthcare system to global supply chain disruptions and international market volatility.”
The proceeds from the Rights Issue will be deployed toward expanding Fidson’s manufacturing infrastructure, strengthening product development pipelines, and improving distribution capacity. These investments are expected to deepen local production, improve access to affordable medicines, and enhance the resilience of the domestic healthcare value chain.
The company also noted that the impact will extend beyond pharmaceuticals into broader economic sectors, including logistics, packaging, research, and employment generation. The transaction, it said, supports Nigeria’s wider industrialisation agenda by reducing import dependence and conserving foreign exchange.
For CardinalStone, the successful execution further reinforces its position in Nigeria’s investment banking landscape. The firm emphasized its track record across capital markets and advisory services, noting over N5tn in advised transactions and leadership in securities trading activity on the Nigerian Exchange.
It also highlighted industry recognition, including “Euromoney’s Africa’s Best Broker Award (2025)” and multiple DealMakers Africa Awards (2026), underscoring its continued visibility within regional financial markets.
Ultimately, the Fidson Rights Issue reflects more than a successful capital raise. It signals continued investor willingness to back real-sector growth stories in Nigeria, particularly in healthcare, where structural demand and national priorities are increasingly aligned with long-term capital formation.